Neurogen Biomarking Enters Partnership Agreement with Tasso to Bring Virtually Painless Blood Collection Technology to Its Alzheimer’s Testing Platform
Neurogen Biomarking and Tasso, Inc. today announced a broad partnership agreement in which Neurogen will adopt Tasso’s virtually painless, needle-free blood collection technology as part of Neurogen’s home-based Alzheimer’s testing services. Neurogen’s advanced brain-health testing ecosystem will incorporate Tasso’s patient-centric collection devices to enable comfortable, user-friendly blood sample collection. The use of the Tasso technology helps expand equitable access to Alzheimer’s-related biomarker testing through a simple, non-invasive blood collection experience.
